Abilita Therapeutics is pioneering drug discovery through its proprietary Enabled Membrane Proteins (EMPs™) technology, which focuses on enhancing the stability and expression of membrane proteins, particularly multi-span membrane proteins (MMPs) such as G Protein-Coupled Receptors (GPCRs) and ion channels. This innovative approach addresses the significant challenges associated with drug discovery in this area, where traditional methods have struggled due to the inherent instability and conformational flexibility of membrane proteins. By utilizing directed evolution, Abilita's EMPs™ provide a means to access and optimize these medically important targets, which are often deemed 'intractable' or 'undruggable,' thereby expanding the potential for developing transformative therapeutics.

The EMP™ technology serves as a foundation for a comprehensive drug discovery platform that integrates various advanced methodologies. This includes antibody discovery, where enhanced antigens improve immunization processes and increase hit diversity, as well as structure-based drug discovery that leverages the conformational stability of EMPs™ for effective hit identification and optimization. Additionally, the platform supports protein-based small molecule discovery through modern screening techniques and sophisticated binding property characterization. By overcoming the limitations traditionally associated with membrane protein targets, Abilita Therapeutics aims to unlock new therapeutic options for diseases such as cancer, diabetes, and neurological disorders.

United States

Abilita Therapeutics is a biotechnology company focused on redefining the druggable landscape for multi-span membrane proteins, including G Protein Coupled Receptors (GPCRs), transporters and ion channels.
We are building a rich pipeline of high-value assets for such targets, with the goal of becoming the leader in discovering and developing first- and best-in-class antibody therapeutics.

Abilita Therapeutics

Company Details